These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 11337222)

  • 1. Evaluation of two in vitro pharmacodynamic simulation models: microfiltration versus centrifugation-filtration.
    Alou L; Sevillano D; Bugella JH; Fuentes F; Gómez-Lus ML; Prieto J
    Int J Antimicrob Agents; 2001 May; 17(5):365-70. PubMed ID: 11337222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin.
    Pontani D; Washton H; Bouchillon S; Johnson J
    Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):413-9. PubMed ID: 9758284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
    Noviello S; Ianniello F; Leone S; Esposito S
    J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.
    Qadri SM; Ueno Y; Burns JJ; Almodovar E; Rabea N
    Chemotherapy; 1992; 38(2):99-106. PubMed ID: 1317282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of CP-74667 compared with four other fluoroquinolones.
    Jones RN; Erwin ME
    Diagn Microbiol Infect Dis; 1992 Aug; 15(6):531-6. PubMed ID: 1330419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BSAC standardized disc susceptibility testing method (version 6).
    Andrews JM;
    J Antimicrob Chemother; 2007 Jul; 60(1):20-41. PubMed ID: 17460026
    [No Abstract]   [Full Text] [Related]  

  • 7. Antimicrobial activity of fluoroquinolones and other antibiotics on 1,116 clinical gram-positive and gram-negative isolates.
    Mascellino MT; Farinelli S; Iegri F; Iona E; De Simone C
    Drugs Exp Clin Res; 1998; 24(3):139-51. PubMed ID: 9825230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity and spectrum of BMS 284756, a new des-F (6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci.
    Jones RN; Pfaller MA; Stilwell M;
    Diagn Microbiol Infect Dis; 2001 Feb; 39(2):133-5. PubMed ID: 11248528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic studies of trovafloxacin and grepafloxacin in vitro against Gram-positive and Gram-negative bacteria.
    Odenholt I; Cars T; Lowdin E
    J Antimicrob Chemother; 2000 Jul; 46(1):35-43. PubMed ID: 10882686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.
    Pong A; Thomson KS; Moland ES; Chartrand SA; Sanders CC
    J Antimicrob Chemother; 1999 Nov; 44(5):621-7. PubMed ID: 10552978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aromatic alcohols and their effect on Gram-negative bacteria, cocci and mycobacteria.
    Fraud S; Rees EL; Mahenthiralingam E; Russell AD; Maillard JY
    J Antimicrob Chemother; 2003 Jun; 51(6):1435-6. PubMed ID: 12716779
    [No Abstract]   [Full Text] [Related]  

  • 12. Antibiotic selective pressure and development of bacterial resistance.
    Kolár M; Urbánek K; Látal T
    Int J Antimicrob Agents; 2001 May; 17(5):357-63. PubMed ID: 11337221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of difloxacin against canine bacterial isolates.
    van den Hoven R; Wagenaar JA; Walker RD
    J Vet Diagn Invest; 2000 May; 12(3):218-23. PubMed ID: 10826834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of clinafloxacin against fluoroquinolone resistant Spanish clinical isolates.
    López-Brea M; Prieto N; Domingo D; de las Cuevas C; Sánchez I; Alarcón T
    Int J Antimicrob Agents; 1999 Jun; 12(1):33-9. PubMed ID: 10389645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model.
    Firsov AA; Vasilov RG; Vostrov SN; Kononenko OV; Lubenko IY; Zinner SH
    J Antimicrob Chemother; 1999 Apr; 43(4):483-90. PubMed ID: 10350376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vitro activity of meropenem versus other extended-spectrum antimicrobials against randomly chosen and selected resistant clinical isolates tested in 26 North American centers.
    Pitkin DH; Sheikh W; Nadler HL
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S238-48. PubMed ID: 9126699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.
    Dalhoff A; Petersen U; Endermann R
    Chemotherapy; 1996; 42(6):410-25. PubMed ID: 8957575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial activity of a new antipseudomonal dual-action drug, Ro 25-0534.
    Jones RN; Sanchez ML
    Diagn Microbiol Infect Dis; 1994 Jan; 18(1):61-8. PubMed ID: 8026159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of E-4868, a new fluoroquinolone with a 7-azetidin ring, compared with ciprofloxacin, ofloxacin and fleroxacin.
    Mirelis B; Navarro F; Miró E; Coll R; Xicota MA; Prats G
    Drugs Exp Clin Res; 1995; 21(4):129-38. PubMed ID: 8529525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against gram-positive cocci.
    Coque TM; Singh KV; Murray BE
    J Antimicrob Chemother; 1996 May; 37(5):1011-6. PubMed ID: 8737152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.